{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T17:05:59Z","timestamp":1748019959675,"version":"3.37.3"},"reference-count":43,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004441","name":"Swedish International Development Cooperation Agency","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004441","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Wellcome Trust\/Medical Research Council (UK)\/UKAID Joint Global Health Trials"},{"DOI":"10.13039\/501100001713","name":"European Developing Countries Clinical Trials Partnership","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>The recent development of highly sensitive and specific point-of-care tests has made it possible to diagnose HIV-associated cryptococcal meningitis within minutes. However, diagnostic advances have not been matched by new antifungal drugs and treatment still relies on old off-patent drugs: amphotericin B, flucytosine and fluconazole. Cryptococcal meningitis treatment is divided in three phases: induction, consolidation and maintenance. The induction phase, aimed at drastically reducing cerebrospinal fluid fungal burden, is key for patient survival. The major challenge in cryptococcal meningitis management has been the optimisation of induction phase treatment using the limited number of available medications, and major progress has recently been made. In this review, we summarise data from key trials which form the basis of current treatment recommendations for HIV-associated cryptococcal meningitis.<\/ns4:p>","DOI":"10.12688\/f1000research.17673.1","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:50:11Z","timestamp":1559026211000},"page":"743","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Recent advances in managing HIV-associated cryptococcal meningitis"],"prefix":"10.12688","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3399-0808","authenticated-orcid":false,"given":"Timoth\u00e9e","family":"Boyer-Chammard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8189-6555","authenticated-orcid":false,"given":"Elvis","family":"Temfack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Alanio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph N.","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"a019760","DOI":"10.1101\/cshperspect.a019760","article-title":"Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis.","volume":"4","author":"K Kwon-Chung","year":"2014","journal-title":"Cold Spring Harb Perspect Med."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"1101-11","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).","volume":"50","author":"P Pappas","year":"2010","journal-title":"Clin Infect Dis."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-2334-10-67","article-title":"Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases.","volume":"10","author":"J Jarvis","year":"2010","journal-title":"BMC Infect Dis."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"873-81","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.","volume":"17","author":"R Rajasingham","year":"2017","journal-title":"Lancet Infect Dis."},{"year":"2016","key":"ref-5","article-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach"},{"year":"2018","key":"ref-6","article-title":"Fact sheet - Latest global and regional statistics on the status of the AIDS epidemic"},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"779-86","DOI":"10.1093\/cid\/cix430","article-title":"Advanced Human Immunodeficiency Virus Disease in Botswana Following Successful Antiretroviral Therapy Rollout: Incidence of and Temporal Trends in Cryptococcal Meningitis.","volume":"65","author":"M Tenforde","year":"2017","journal-title":"Clin Infect Dis."},{"year":"2017","key":"ref-8","article-title":"Test CryptoPS"},{"year":"2017","key":"ref-9","article-title":"CrAg LFA"},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"2435-44","DOI":"10.1093\/jac\/dkt221","article-title":"Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.","volume":"68","author":"A Loyse","year":"2013","journal-title":"J Antimicrob Chemother."},{"year":"2018","key":"ref-11","article-title":"Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection"},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"123-30","DOI":"10.1086\/588792","article-title":"High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial.","volume":"47","author":"T Bicanic","year":"2008","journal-title":"Clin Infect Dis."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"1775-83","DOI":"10.1086\/599112","article-title":"A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.","volume":"48","author":"P Pappas","year":"2009","journal-title":"Clin Infect Dis."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"e67311","DOI":"10.1371\/journal.pone.0067311","article-title":"A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi.","volume":"8","author":"C Rothe","year":"2013","journal-title":"PLoS One."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"486-91","DOI":"10.4103\/1947-2714.117318","article-title":"Cryptococcal meningoencephalitis in human immunodeficiency virus\/acquired immunodeficiency syndrome in douala, cameroon: a cross sectional study.","volume":"5","author":"H Luma","year":"2013","journal-title":"N Am J Med Sci."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"e110285","DOI":"10.1371\/journal.pone.0110285","article-title":"A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi.","volume":"9","author":"K Gaskell","year":"2014","journal-title":"PLoS One."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"2126-9","DOI":"10.1093\/cid\/cix613","article-title":"Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program.","volume":"65","author":"T Beyene","year":"2017","journal-title":"Clin Infect Dis."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"1291-302","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis.","volume":"368","author":"J Day","year":"2013","journal-title":"N Engl J Med."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"629-37","DOI":"10.1016\/S1473-3099(13)70078-1","article-title":"Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries.","volume":"13","author":"A Loyse","year":"2013","journal-title":"Lancet Infect Dis."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"76-81","DOI":"10.1016\/j.jinf.2011.10.014","article-title":"Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis.","volume":"64","author":"C Muzoora","year":"2012","journal-title":"J Infect."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"1363-70","DOI":"10.1097\/QAD.0b013e328354b419","article-title":"A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis.","volume":"26","author":"A Jackson","year":"2012","journal-title":"AIDS."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"338-44","DOI":"10.1086\/649861","article-title":"Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi.","volume":"50","author":"J Nussbaum","year":"2010","journal-title":"Clin Infect Dis."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1004-17","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa.","volume":"378","author":"S Molloy","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"CD005647","DOI":"10.1002\/14651858.CD005647.pub3","article-title":"Treatment for HIV-associated cryptococcal meningitis.","volume":"7","author":"M Tenforde","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"225-32","DOI":"10.1086\/653606","article-title":"Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.","volume":"51","author":"R Hamill","year":"2010","journal-title":"Clin Infect Dis."},{"key":"ref-26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00090-17","article-title":"Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.","volume":"61","author":"J Lestner","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"393-401","DOI":"10.1093\/cid\/ciy515","article-title":"Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial.","volume":"68","author":"J Jarvis","year":"2019","journal-title":"Clin Infect Dis."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1186\/s13063-018-3026-4","article-title":"AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.","volume":"19","author":"D Lawrence","year":"2018","journal-title":"Trials."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"47-54","DOI":"10.1086\/313603","article-title":"Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups.","volume":"30","author":"J Graybill","year":"2000","journal-title":"Clin Infect Dis."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"736-45","DOI":"10.1093\/cid\/cit794","article-title":"Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes.","volume":"58","author":"J Jarvis","year":"2014","journal-title":"Clin Infect Dis."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"542-54","DOI":"10.1056\/NEJMoa1509024","article-title":"Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis.","volume":"374","author":"J Beardsley","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"1494-1501","DOI":"10.1093\/cid\/ciy725","article-title":"Do intra-cerebral cytokine responses explain the harmful effects of dexamethasone in HIV-associated cryptococcal meningitis?","volume":"68","author":"J Beardsley","year":"2019","journal-title":"Clin Infect Dis."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"2487-98","DOI":"10.1056\/NEJMoa1312884","article-title":"Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis.","volume":"370","author":"D Boulware","year":"2014","journal-title":"N Engl J Med."},{"year":"2017","key":"ref-34","article-title":"Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy"},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"344-6","DOI":"10.1093\/infdis\/jiy448","article-title":"Understanding Causal Pathways in Cryptococcal Meningitis Immune Reconstitution Inflammatory Syndrome.","volume":"219","author":"J Jarvis","year":"2019","journal-title":"J Infect Dis."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"26-34","DOI":"10.1097\/QCO.0b013e32835c21d1","article-title":"Cryptococcal immune reconstitution inflammatory syndrome.","volume":"26","author":"N Longley","year":"2013","journal-title":"Curr Opin Infect Dis."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"1532-8","DOI":"10.1086\/652652","article-title":"Early versus Delayed Initiation of Antiretroviral Therapy for Concurrent HIV Infection and Cryptococcal Meningitis in Sub\u2010Saharan Africa.","volume":"50","author":"A Makadzange","year":"2010","journal-title":"Clin Infect Dis."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"CD009012","DOI":"10.1002\/14651858.CD009012.pub3","article-title":"Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis.","volume":"7","author":"I Eshun-Wilson","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"1741-51","DOI":"10.1056\/NEJMoa040573","article-title":"Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.","volume":"351","author":"G Thwaites","year":"2004","journal-title":"N Engl J Med."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"1549-56","DOI":"10.1056\/NEJMoa021334","article-title":"Dexamethasone in adults with bacterial meningitis.","volume":"347","author":"J de Gans","year":"2002","journal-title":"N Engl J Med."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"3758-66","DOI":"10.1128\/AAC.00212-12","article-title":"The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections.","volume":"56","author":"B Zhai","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"809-18","DOI":"10.1016\/S1473-3099(16)00074-8","article-title":"Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.","volume":"16","author":"J Rhein","year":"2016","journal-title":"Lancet Infect Dis."},{"article-title":"Adjunctive sertraline in HIV-associated cryptococcal meningitis","year":"2018","author":"J Rhein","key":"ref-43"}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-743\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-743\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-743\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T04:55:13Z","timestamp":1559192113000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-743\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":43,"URL":"https:\/\/doi.org\/10.12688\/f1000research.17673.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.19325.r48696","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.19325.r48697","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"type":"electronic","value":"2046-1402"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-743\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.19325.r48697, Carlos Franco-Paredes, Department of Medicine, Division of Infectious Diseases, University of Colorado Denver, Colorado, USA, 28 May 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-743\/v1#referee-response-48697","order":0,"name":"referee-response-48697","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.19325.r48696, Thomas Benfield, Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark, 28 May 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-743\/v1#referee-response-48696","order":1,"name":"referee-response-48696","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"T.B-C., A.A., J.N.J., T.S.H. and O.L. are all investigators on the AMBITION trial which is jointly funded through the European Developing Countries Clinical Trials Partnership (EDCTP), the Swedish International Development Cooperation Agency (SIDA), and the Wellcome Trust\/Medical Research Council (UK)\/UKAID Joint Global Health Trials. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}